Neurosteroids, stress and depression: Potential therapeutic opportunities

Neuroscience and Biobehavioral Reviews

Volumn 37, Issue 1, 2013, Pages 109-122

  Zorumski, Charles F ^a   Paul, Steven M ^b   Izumi, Yukitoshi ^a   Covey, Douglas F ^a   Mennerick, Steven ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Allopregnanolone; Anxiety; Depression; Hippocampus; Neuroactive steroids; Stress

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ALPRAZOLAM; ALTHESIN; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CLOZAPINE; DIAZEPAM; EMAPUNIL; FINASTERIDE; FLUOXETINE; FLUVOXAMINE; GANAXOLONE; MIRTAZAPINE; NEUROSTEROID; OLANZAPINE; PAROXETINE; PREGNENOLONE; SERTRALINE;

ALCOHOLISM; ANXIETY DISORDER; BRAIN REGION; CAUSAL ATTRIBUTION; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; EPILEPSY; GABAERGIC TRANSMISSION; HORMONE BLOOD LEVEL; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; IMMUNOREACTIVITY; MIGRAINE; MOOD DISORDER; NERVE CELL; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; STEROIDOGENESIS; STRESS; UNSPECIFIED SIDE EFFECT;

ANIMALS; BRAIN; DEPRESSION; GAMMA-AMINOBUTYRIC ACID; HUMANS; MOLECULAR TARGETED THERAPY; NEUROTRANSMITTER AGENTS; RECEPTORS, GABA-A; STRESS, PSYCHOLOGICAL;

EID: 84873747941     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2012.10.005     Document Type: Review

References (203)

1. aan het Rot M., Zarate C.A., Charney D.S., Mathew S.J. Ketamine for depression: where do we go from here?. Biological Psychiatry 2012, 72:537-547.
2. Admon R., Lubin G., Stern O., Rosenberg K., Sela L., Ben-Ami H., Hendler T. Human vulnerability to stress depends on amygdala's predisposition and hippocampal plasticity. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:14120-14125.
3. Agis-Balboa R.C., Pinna G., Pibiri F., Kadriu B., Costa E., Guidotti A. Down-regulation of neurosteroid biosynthesis in corticolimbic circuits mediates social isolation-induced behavior in mice. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:18736-18741.
4. Agís-Balboa R.C., Pinna G., Zhubi A., Maloku E., Veldic M., Costa E., Guidotti A. Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:14602-14607.
5. Airan R.D., Meltzer L.A., Roy M., Gong Y., Chen H., Deisseroth K. High-speed imaging reveals neurophysiological links to behavior in an animal model of depression. Science 2007, 317:819-823.
6. A receptors. The Journal of Physiology 2004, 558:59-74. (London).
7. A receptors: mechanism and involvement of a residue in the M2 region of the α subunit. The Journal of Physiology 2001, 532:673-684. (London).
8. Akk G., Covey D.F., Evers A.S., Mennerick S., Zorumski C.F., Steinbach J.H. Kinetic and structural determinants for GABA-A receptor potentiation by neuroactive steroids. Current Neuropharmacology 2010, 8:18-25.
9. A receptors. Pharmacology & Therapeutics 2007, 116:35-57.
10. Akk G., Li P., Bracamontes J., Reichert D.E., Covey D.F., Steinbach J.H. Mutations of the GABA-A receptor alpha1 subunit M1 domain reveal unexpected complexity for modulation by neuroactive steroids. Molecular Pharmacology 2008, 74:614-627.
11. Akk G., Shu H-J., Wang C., Steinbach J.H., Zorumski C.F., Covey D.F., Mennerick S. Neurosteroid access to the GABA-A receptor. The Journal of Neuroscience 2005, 25:11606-11613.
12. Alakoskela J.M., Covey D.F., Kinnunen P.K. Lack of enantiomeric specificity in the effects of anesthetic steroids on lipid bilayers. Biochimica et Biophysica Acta 2007, 1768:131-145.
13. Altomare G., Capella G.L. Depression circumstantially related to the administration of finasteride for androgenetic alopecia. The Journal of Dermatology 2002, 29:665-669.
14. Barbaccia M.L. Neurosteroidogenesis: relevance to neurosteroid actions in brain and modulation by psychotropic drugs. Critical Reviews in Neurobiology 2004, 16:67-74.
15. Baulieu E.E. Steroid hormones in the brain: several mechanisms. Steroid Hormone Regulation of the Brain 1981, 3-14. Pergamon Press, Oxford. K. Fuxe, J.A. Gustafsson, L. Wetterberg (Eds.).
16. Baulieu E.E. Neurosteroids: of the nervous system, by the nervous system, for the nervous system. Recent Progress in Hormone Research 1997, 52:1-32.
17. A receptors: form, pharmacology, and function. The Journal of Neuroscience 2009, 29:12757-12763.
18. A receptor. Nature Reviews. Neuroscience 2005, 6:565-575.
19. Benes F.M., Lim B., Matzilevich D., Sugguraju S., Walsh J.P. Circuitry-based gene expression profiles in GABA cells of the trisynaptic pathway in schizophrenics versus bipolar. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:20935-20940.
20. Bianchi M., Baulieu E.E. 3β-methoxy-pregnenolone (MAP4343) as an innovative therapeutic approach for depressive disorders. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:1713-1718.
21. Bitran D., Foley M., Audette D., Leslie N., Frye C.A. Activation of peripheral mitochondrial benzodiazepine receptors in the hippocampus stimulates allopregnanolone synthesis and produces anxiolytic-like effects in the rat. Psychopharmacology 2000, 151:64-71.
22. Brambilla P., Perez J., Barale F., Schettini G., Soares J.C. GABAergic dysfunction in mood disorders. Molecular Psychiatry 2003, 8:721-737.
23. A receptors: their function in the CNS and implications for disease. Neuron 2012, 73:23-34.
24. Brown N., Kerby J., Bonnert T.P., Whiting P.J., Wafford K.A. Pharmacological characterization of a novel cell line expressing human alpha(4)beta(3)delta GABA(A) receptors. British Journal of Pharmacology 2002, 136:965-974.
25. Buckholtz J.W., Meyer-Lindenberg A. Psychopathology and the human connectome: toward a transdiagnostic model of risk for mental illness. Neuron 2012, 74:990-1004.
26. Capponi A.M., Rossier M.F., Davies E., Vallotton M.B. Calcium stimulates steroidogenesis in permeabilized bovine adrenal cortical cells. The Journal of Biological Chemistry 1988, 263:16113-16117.
27. Casellas P., Galiegue S., Basile A.S. Peripheral benzodiazepine receptors and mitochondrial function. Neurochemistry International 2002, 40:475-486.
28. Charalampopoulos I., Remboutsika E., Margioris A.N., Gravanis A. Neurosteroids as modulators of neurogenesis and neuronal survival. Trends in Endocrinology and Metabolism 2008, 19:300-307.
29. Charradi N., Rossier M.F., Vallotton M.B., Capponi A.M. Calcium stimulates intramitochondrial cholesterol transfer in bovine adrenal glomerulosa cells. The Journal of Biological Chemistry 1996, 271:25971-25975.
30. Chen M-K., Guilarte T.R. Translocator protein 18kDa (TSPO): molecular sensor of brain injury and repair. Pharmacology & Therapeutics 2008, 118:1-17.
31. Chen Z.W., Chen L.H., Akentieva N., Lichti C.F., Darbandi R., Hastings R., Covey D.F., Reichert D.E., Townsend R.R., Evers A.S. A neurosteroid analogue photolabeling reagent labels the cochicine-binding site on tubulin: a mass spectrometric analysis. Electrophoresis 2012, 33:666-674.
32. A receptors. Trends in Neurosciences 2010, 33:299-306.
33. A receptor modulation: evidence for a low affinity interaction. Journal of Neurophysiology 2009, 102:1254-1264.
34. A receptors: similarities and differences with neurosteroid actions. British Journal of Pharmacology 2010, 160:130-141.
35. Chisari M., Wu K., Zorumski C.F., Mennerick S. Hydrophobic anions potently and uncompetitively antagonize GABA-A receptor function in the absence of a conventional binding site. British Journal of Pharmacology 2011, 164:667-680.
36. Covey D.F. ent-Steroids: novel tools for studies of signaling pathways. Steroids 2009, 74:577-585.
37. A receptors. Brain Research Reviews 2001, 37:91-97.
38. Covey D.F., Nathan D., Kalkbrenner M., Nilsson K.R., Hu Y., Zorumski C.F., Evers A.S. Enantioselectivity of pregnanolone-induced gamma-aminobutyric acid (A) receptor modulation and anesthesia. The Journal of Pharmacology and Experimental Therapeutics 2000, 293:1009-1016.
39. Crawley J.N., Glowa J.R., Majewska M.D., Paul S.M. Anxiolytic activity of an endogenous adrenal steroid. Brain Research 1986, 398:382-385.
40. A-receptor clustering results in enhanced anxiety and a bias for threat cues. Nature Neuroscience 1999, 2:833-839.
41. Danovich L., Veenman L., Leschiner S., Lahav M., Shuster V., Weizman A., Gavish M. The influence of clozapine treatment and other antipsychotics on the 18kDa translocator protein, formerly named the peripheral-type benzodiazepine receptor and steroid production. European Neuropsychopharmacology 2008, 18:24-33.
42. Darbandi-Tonkabon R., Hastings W.R., Zeng C.M., Akk G., Manion B.D., Bracamontes J.R., Steinbach J.H., Mennerick S.J., Covey D.F., Evers A.S. Photoaffinity labeling with a neuroactive steroid analogue. 6-azi-pregnanolone labels voltage-dependent anion channel-1 in rat brain. The Journal of Biological Chemistry 2003, 278:13196-13206.
43. Dong E., Matsumoto K., Uzunova V., Sugaya I., Takahata H., Nomura H., Watanabe H., Costa E., Guidotti A. Brain 5α-dihydroprogesterone and allopregnanolone synthesis in a mouse model of protracted social isolation. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:2849-2854.
44. Do Rego J.L., Seong J.Y., Burel D., Leprince J., Vaudry D., Luu-The V., Tonon M-C., Tsutsui K., Pelletier G., Vaudry H. Regulation of neurosteroid biosynthesis by neurotransmitters and neuropeptides. Frontiers in Endocrinology 2012, 3:1-15.
45. Earnheart J.C., Schweizer C., Crestani F., Iwasato T., Itohara S., Mohler H., Luscher B. GABAergic control of adult hippocampal neurogenesis in relation to behavior indicative of trait anxiety and depression states. The Journal of Neuroscience 2007, 27:3845-3854.
46. A receptor-mediated current. The Journal of Physiology 2003, 550:679-691. (London).
47. Esser C., Romeo E., Baghai T.C., Di Michele F., Schule C., Pasini A., Zwanzger P., Padgerg F., Rupprecht R. Neuroactive steroids as modulators of depression and anxiety. Neuroscience 2006, 138:1041-1048.
48. A receptors. The Journal of Pharmacology and Experimental Therapeutics 2010, 333:404-413.
49. A receptors. Nature Reviews. Neuroscience 2005, 6:215-229.
50. Ferrarese C., Appollonio I., Bianchi G., Frigo M., Marzorati C., Pecora N., Perego M., Pierpaoli C., Frattola L. Benzodiazepine receptors and diazepam binding inhibitor: a possible link between stress, anxiety and the immune system. Psychoneuroendocrinology 1993, 18:3-22.
51. Ferrarese C., Mennini T., Pecora N., Pierpaoli C., Frigo M., Marzorati C., Gobbi M., Bizzi A., Codegoni A., Garattini S. Diazepam binding inhibitor (DBI) increases after acute stress in rat. Neuropharmacology 1991, 30:1445-1452.
52. Frye C.A., Paris J.J., Walf A.A., Rusconi J.C. Effects and mechanisms of 3α5α-THP on emotion, motivation and reward functions involving pregnane xenobiotic receptor. Frontiers in Neuroscience 2012, 5:1-18.
53. Gabbay V., Mao X., Klein R.G., Ely B.A., Babb J.S., Panzer A.M., Alonso C.M., Shungu D.C. Anterior cingluate cortex γ-aminobutyric acid in depressed adolescents. Archives of General Psychiatry 2011, 69:139-149.
54. A receptor complex: the pharmacological properties and therapeutic potential of epalons. Critical Reviews in Neurobiology 1995, 9:207-227.
55. Gibbs T.T., Russek S.J., Farb D.H. Sulfated steroids as endogenous modulators. Pharmacology, Biochemistry, and Behavior 2006, 8:555-567.
56. Girdler S.S., Klatzkin R. Neurosteroids in the context of stress: implications for depressive disorders. Pharmacology & Therapeutics 2007, 116:125-139.
57. A receptor subunits are necessary for tonic inhibition in the hippocampus?. The Journal of Neuroscience 2008, 28:1421-1426.
58. Griffin L.D., Mellon S.H. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:13512-13517.
59. Guarneri P., Russo D., Cascio C., De Leo G., Piccoli F., Guarneri R. Induction of neurosteroid synthesis by NMDA receptors in isolated rat retina: a potential early event in excitotoxicity. The European Journal of Neuroscience 1998, 10:1752-1763.
60. Gunn B.G., Brown A.R., Lambert J.J., Belelli D. Neurosteroids and GABAA receptor interactions: a focus on stress. Frontiers in Neuroscience 2011, 5:1-20.
61. Harrison N.L., Vicini S., Barker J.L. A steroid anesthetic prolongs inhibitory postsynaptic currents in cultured rat hippocampal neurons. The Journal of Neuroscience 1987, 7:604-609.
62. A receptors. Pharmacology & Therapeutics 2007, 116:20-34.
63. A receptors. Molecular Neurobiology 1998, 18:35-86.
64. Hewitt S.A., Wamsteeker J.I., Kruz E.U., Bains J.S. Altered chloride homeostasis removes synaptic inhibitory constraint of the stress axis. Nature Neuroscience 2009, 12:438-443.
65. A receptors in nervous system pathologies. Current Opinion in Neurobiology 2011, 22:1-7.
66. A receptors. Neuropharmacology 2008, 56:149-154.
67. A receptors via two discrete transmembrane sites. Nature 2006, 444:486-489.
68. A receptors important targets for sedative/hypnotic drugs?. The Journal of Neuroscience 2012, 32:3887-3897.
69. Iglehart J.K. The mental health maze and the call for transformation. The New England Journal of Medicine 2004, 350:507-514.
70. Insel T., Sahakian B.J. A plan for mental illness. Nature 2012, 483:269.
71. Irwig M.S. Persistent sexual side effects of finasteride: could they be permanent?. The Journal of Sexual Medicine 2012, (epub ahead of print).
72. Irwig M.S. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. The Journal of Clinical Psychiatry 2012, 73:1220-1223.
73. Irwin R.W., Wang J.M., Chen S., Brinton R.D. Neuroregenerative mechanisms of allopregnanolone in Alzheimer's disease. Frontiers in Endocrinology 2012, 2:1-14.
74. Izumi Y., Clifford D.B., Zorumski C.F. Inhibition of long-term potentiation by NMDA-mediated nitric oxide release. Science 1992, 257:1273-1276.
75. Izumi Y., Clifford D.B., Zorumski C.F. Low concentrations of N-methyl-D-aspartate inhibit the induction of long-term potentiation in rat hippocampal slices. Neuroscience Letters 1992, 137:245-248.
76. Izumi Y., Murayama K., Tokuda K., Krishnan K., Covey D.F., Zorumski C.F. GABAergic neurosteroids mediate the effects of ethanol on long-term potentiation in rat hippocampal slices. The European Journal of Neuroscience 2007, 26:1881-1888.
77. Izumi Y., Tokuda K., Zorumski C.F. Long-term potentiation inhibition by low-level N-methyl-D-aspartate receptor activation involves calcineurin, nitric oxide and p38 mitogen-activated protein kinase. Hippocampus 2008, 18:258-265.
78. Jin X., Covey D.F., Steinbach J.H. Kinetic analysis of voltage-dependent potentiation and block of the glycine alpha 3 receptor by a neuroactive steroid analogue. The Journal of Physiology 2009, 587:981-987. (London).
79. A receptor channel pharmacology. Current Pharmaceutical Design 2005, 11:1867-1885.
80. Kato K., Zorumski C.F. Nitric oxide inhibitors facilitate the induction of hippocampal long-term potentiation by modulating NMDA responses. Journal of Neurophysiology 1993, 70:1260-1263.
81. A receptors by ent-androgens. European Journal of Medicinal Chemistry 2008, 43:107-113.
82. Kawano T., Soga T., Chi H., Eguchi S., Yamazaki F., Kumagai N., Yokoyama M. Role of the neurosteroid allopregnanolone in the hyperalgesic behavior induced by painful nerve injury in rats. Journal of Anesthesia 2011, 25:942-945.
83. Kawano T., Soga T., Chi H., Eguchi S., Yamazaki F., Yokoyama M. The involvement of the neurosteroid allopregnanolone n the antihyperalgesic effect of paroxetine in a rat model of neuropathic pain. Neuroreport 2011, 22:984-988.
84. Kim H.J., Kang S.S., Cho G.J., Choi W.S. Steroidogenic acute regulatory protein: its presence and function in brain neurosteroidogenesis. Archives of Histology and Cytology 2004, 67:383-392.
85. Kim J.J., Foy M.R., Thompson R.F. Behavioral stress modifies hippocampal plasticity through N-methyl-D-aspartate receptor activation. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:4750-4753.
86. Kimoto T., Tsurugizwa T., Ohta Y., Makino J., Tamura H-O., Hojo Y., Takata N., Kawato S. Neurosteroid synthesis by cytochrome p450-containing systems localized in rat brain hippocampal neurons: N-methyl-D-aspartate and calcium-dependent synthesis. Endocrinology 2001, 142:3578-3589.
87. King S.R., Manna P.R., Ishii T., Syapin P.J., Ginsberg S.D., Wilson K., Walsh L.P., Parker K.L., Stocco D.M., Smith R.G., Lamb D.J. An essential component in steroid synthesis, the steroidogenic acute regulatory protein, is expressed in discrete regions of the brain. The Journal of Neuroscience 2002, 22:10613-10620.
88. Korpi E.R., Sinkkonen S.T. GABA(A) receptor subtypes as targets for neuropsychiatric drug development. Pharmacology & Therapeutics 2006, 109:12-32.
89. A) receptors. Journal of Medicinal Chemistry 2012, 55:1334-1345.
90. Langmade S.J., Gale S.E., Frolov A., Mohri I., Suzuki K., Mellon S.H., Walkley S.U., Covey D.H., Schaffer J.E., Ory D.S. Pregnane X receptor (PXR) activation: a mechanism for neuroprotection in a mouse model of Niemann-Pick C disease. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:13807-13812.
91. Lavaque E., Sierra A., Azcoitia I., Garcia-Segura.L.M. Steroidogenic acute regulatory protein in the brain. Neuroscience 2006, 138:741-747.
92. A receptor. Molecular Pharmacology 2007, 71:1582-1590.
93. Li P., Covey D.F., Steinbach J.H., Akk G. Dual potentiating and inhibitory actions of a benz[e]indene neurosteroid analog on recombinant alpha1beta2gamma2 GABA-A receptors. Molecular Pharmacology 2006, 69:2015-2026.
94. Li P., Shu H.-J., Wang C., Mennerick S., Zorumski C.F., Covey D.F., Steinbach J.H., Akk G. Neurosteroid migration to intracellular compartments reduces steroid concentration in the membrane and diminishes GABA-A receptor potentiation. The Journal of Physiology 2007, 584:789-800. (London).
95. Luscher B., Shen Q., Sahir N. The GABAergic deficit hypothesis of major depressive disorder. Molecular Psychiatry 2011, 16:383-406.
96. Machado-Vieira R., Salvadore G., Diazgranados N., Zarate C.A. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacology & Therapeutics 2009, 123:143-150.
97. Maguire J., Mody I. GABA(A)R plasticity during pregnancy: relevance to postpartum depression. Neuron 2008, 59:207-213.
98. Majeed Y., Amer M.S., Agarwal A.K., McKeown L., Porter K.E., O'Regan D.J., Naylor J., Fishwick C.W., Muraki K., Beech D.J. Stereo-selecive inhibition of transient receptor potential TRPC5 cation channels by neuroactive steroids. British Journal of Pharmacology 2011, 162:1509-1520.
99. Majewska M.D., Harrison N.L., Schwartz R.D., Barker J.L., Paul S.M. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 1986, 232:1004-1007.
100. Majewska M.D., Mienville J-M., Vicini S. Neurosteroid pregnenolone sulfate antagonizes electrophysiological responses to GABA in neurons. Neuroscience Letters 1988, 90:279-284.
101. 2H NMR spectroscopy. Journal of Medicinal Chemistry 1991, 34:1700-1703.
102. Malayev A.A., Gibbs T.T., Farb D.H. Inhibition of the NMDA response by pregnenolone sulfate reveals subtype selective modulation of NMDA receptors by sulfated steroids. British Journal of Pharmacology 2001, 135:901-909.
103. Manji H., Kato T., Di Prospero N.A., Ness S., Beal M.F., Krams M., Chen G. Impaired mitochondrial function in psychiatric disorders. Nature Reviews. Neuroscience 2012, 13:293-307.
104. Marsden W.N. Stressor-induced NMDAR dysfunction as a unifying hypothesis for the aetiology, pathogenesis and comorbidity of clinical depression. Medical Hypotheses 2011, 77:508-528.
105. Marx C.E., Bradford D.W., Hamer R.M., Naylor J.C., Allen T.B., Lieberman J.A., Strauss J.L., Kilts J.D. Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. Neuroscience 2011, 191:78-90.
106. Marx C.E., Keefe R.S., Buchanan R.W., Hamer R.M., Kilts J.D., Bradford D.W., Strauss J.L., Naylor J.C., Payne V.M., Lieberman J.A., Savitz A.J., Leimone L.A., Dunn L., Porcu P., Morrow A.L. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology 2009, 34:1885-1903.
107. McCauley L.D., Park C.H., Lan N.C., Tomich J.M., Shively J.E., Gee K.W. Benzodiazepines and peptides stimulate pregnenolone synthesis in brain mitochondria. European Journal of Pharmacology 1995, 276:145-153.
108. A receptors. Molecular Pharmacology 2004, 65:1191-1197.
109. A receptors of a neuroactive steroid that negatively modulates glutamate neurotransmission and augments GABA neurotransmission. Molecular Pharmacology 2001, 60:732-741.
110. Midzak A., Akula N., Lecanu L., Papadopoulos V. Novel androstenetriol interacts with the mitochondrial translocator protein and controls steroidogenesis. The Journal of Biological Chemistry 2011, 286:9875-9887.
111. Midzak A., Rone M., Aghazadeh Y., Culty M., Papadopoulos V. Mitochondrial protein import and the genesis of steroidogenic mitochondria. Molecular and Cellular Endocrinology 2011, 336:70-79.
112. A receptors. Frontiers in Cellular Neuroscience 2012, 6:1-6.
113. Mokdad A.H., Marks J.S., Stroup D.F., Gerberding J.E. Actual causes of death in the United States, 2000. JAMA: the Journal of the American Medical Association 2004, 291:1238-1245.
114. Monaghan E.P., Navalta L.A., Shum L., Ashbrook D.W., Lee D.A. Initial human experience with ganaxalone, a neuroactive steroid with antiepileptic activity. Epilepsia 1997, 38:1026-1031.
115. Morgan M., Whitwam J.G. Althesin. Anaesthesia 1985, 40:121-123.
116. Morrow A.L., Janis G.C., VanDoren M.J., Matthews D.B., Samson H.H., Janak P.H., Grant K.A. Neurosteroids mediate pharmacological effects of ethanol: a new mechanism of ethanol action?. Alcoholism, Clinical, and Experimental Research 1999, 23:1933-1940.
117. Morrow A.L., Porcu P., Boyd K.N., Grant K.A. Hypothalamic-pituitary-adrenal axis modulation of GABAergic neuroactive steroids influences ethanol sensitivity and drinking behavior. Dialogues in Clinical Neuroscience 2006, 8:463-477.
118. Morrow A.L., VanDoren M.J., Penland S.N., Matthews D.B. The role of GABAergic neuroactive steroids in ethanol action, tolerance and dependence. Brain Research Reviews 2001, 37:98-109.
119. Moussavi S., Chatterji S., Verdes E., Tandon A., Patel V., Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007, 370:851-858.
120. Nestler E.J., Hyman S.E. Animal models of neuropsychiatric disorders. Nature Neuroscience 2010, 13:1161-1169.
121. Newcomer J.W., Hennekens C.H. Severe mental illness and risk of cardiovascular disease. JAMA: the Journal of the American Medical Association 2007, 298:1794-1796.
122. Nilsson K.R., Zorumski C.F., Covey D.F. Neurosteroid analogues. 6. The synthesis and GABAA receptor pharmacology of enantiomers of dephydroepiandrosterone sulfate, pregnenolone sulfate, and (3 alpha, 5 beta)-3-hydroxypregnan-20-one sulfate. Journal of Medicinal Chemistry 1998, 41:2604-2613.
123. Nin M.S., Salles F.B., Azeredo L.A., Frazon A.P., Gomez R., Barros H.M. Antidepressant effect and changes of GABA(A) receptor gamma2 subunit after hippocampal administration of allopregnanolone in rats. Journal of Psychopharmacology 2008, 22:477-485.
124. O'Dell L.E., Purdy R.H., Covey D.F., Richardson H.N., Roberto M., Koob G.F. Epipregnanolone and a novel synthetic neuroactive steroid reduce alcohol self-administration in rats. Pharmacology, Biochemistry, and Behavior 2005, 81:543-550.
125. Olney J.W., Labruyere J., Wang G., Wozniak D.F., Price M.T., Sesma M.A. NMDA antagonist neurotoxicity: mechanism and prevention. Science 1991, 254:1515-1518.
126. A receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology 2009, 56:141-148.
127. Owen D.R., Matthews P.M. Imaging brain microglial activation using positron emission tomography and translocator protein-specific radioligands. International Review of Neurobiology 2011, 101:19-39.
128. Papadopoulos V., Baraldi M., Guilarte T.R., Knudsen T.B., Lacapere J-J., Lindemann P., Norenberg M.D., Nutt D., Weizman A., Zhang M-R., Gavish M. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends in Pharmacological Sciences 2006, 27:402-409.
129. Papadopoulos V., Guarneri P., Krueger K.E., Guidotti A., Costa E. Pregnenolone biosynthesis in C6-2B glioma cell mitochondria: regulation by a mitochondrial diazepam binding inhibitor receptor. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:5113-5117.
130. Paradiso K., Sabey K., Evers A.S., Zorumski C.F., Covey D.F., Steinbach J.H. Steroid inhibition of rat neuronal nicotinic α4β2 receptors expressed in HEK 293 cells. Molecular Pharmacology 2000, 58:341-351.
131. Park-Chung M., Wu F.S., Purdy R.H., Malayev A.A., Gibbs T.T., Farb D.H. Distinct sites for inverse modulation of N-methyl-D-aspartate receptors by sulfated steroids. Molecular Pharmacology 1997, 52:1113-1123.
132. Patchev V.K., Hassan A.H., Holsboer D.F., Almeida O.F. The neurosteroid tetrahydroprogesterone attenuates the endocrine response to stress and exerts glucocorticoid-like effects on vasopressin gene transcription in the rat hypothalamus. Neuropsychopharmacology 1996, 15:533-540.
133. Patchev V.K., Shoaib M., Holsboer F., Almeida O.F. The neurosteroid tetrahydroprogesterone counteracts corticotrophin-releasing hormone-induced anxiety and alters the release and gene expression of corticotrophin-releasing hormone in the rat hypothalamus. Neuroscience 1994, 62:265-271.
134. A channels are responsible for the potent analgesic effects of 5α-reduced neuroactive steroids. Pain 2005, 114:429-443.
135. Paul S.M., Purdy R.H. Neuroactive steroids. The FASEB Journal 1992, 6:2311-2322.
136. Phillipps G.H. Structure-activity relationships in steroidal anaesthetics. Molecular Mechanisms in General Anaesthesia 1974, 32-46. Churchill Livingstone, Edinburgh. M.J. Halsey, R.A. Millar, J.A. Sutton (Eds.).
137. Pibiri F., Nelson M., Guidotti A., Costa E., Pinna G. Decreased corticolimbic allopregnanolone expression during social isolation enhances contextual fear: a model relevant for posttraumatic stress disorder. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:5567-5572.
138. Pinna G., Dong E., Matsumoto K., Costa E., Guidotti A. In socially isolated mice, the reversal of brain allopregnanolone down-regulation mediates the anti-aggressive action of fluoxetine. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:2035-2040.
139. Pollak D.D., Monje F.J., Zuckerman L., Denny C.A., Drew M.R., Kandel E.R. An animal model of a behavioral intervention for depression. Neuron 2008, 60:149-161.
140. Popoli M., Yan Z., McEwen B.S., Sanacora G. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nature Reviews. Neuroscience 2012, 13:22-37.
141. A receptors mediate phasic and tonic forms of inhibition in hippocampal pyramidal neurons. Journal of Neurophysiology 2006, 96:846-857.
142. Prince M., Patel V., Saxena S., Maj M., Maselko J., Phillips M.R., Rahman A. No health without mental health. Lancet 2007, 370:859-877.
143. Purdy R.H., Morrow A.L., Moore P.H., Paul S.M. Stress-induced elevations of γ-aminobutyric acid type A receptor-active steroids in the rat brain. Proceedings of the National Academy of Sciences of the United States of America 1991, 88:4553-4557.
144. Rahimi-Ardabili B., Pourandarjani R., Habibollahi P., Mualeki A. Finasteride induced depression: a prospective study. BMC Clinical Pharmacology 2006, 6:7.
145. Rasmusson A.M., Pinna G., Paliwal P., Weisman D., Gottschalk C., Charney D., Krystal J., Guidotti A. Decreased cerebrospinal fluid allopregnanolone levels in women with posttraumatic stress disorder. Biological Psychiatry 2006, 60:704-713.
146. Reddy D.S., Rogawski M.A. Neurosteroid replacement therapy for catamenial epilepsy. Neurotherapeutics 2009, 6:392-401.
147. Ressler K.J., Mayberg H.S. Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nature Neuroscience 2007, 10:1116-1124.
148. Romeo E., Auta J., Kozikowski A.P., Ma D., Papadopoulos V., Puia G., Costa E., Guidotti A. 2-Aryl-3-indoleacetamides (FGIN-1): a new class of potent and specific ligands for the mitochondrial DBI receptor (MDR). The Journal of Pharmacology and Experimental Therapeutics 1992, 262:971-978.
149. Romeo E., Strohle A., Spalletta G., di Michele F., Hermann B., Holsboer F., Pasini A., Rupprecht R. Effects of antidepressant treatment on neuroactive steroids in major depression. The American Journal of Psychiatry 1998, 155:910-913.
150. Rone M.B., Fan J., Papadopoulos V. Cholesterol transport in steroid biosynthesis: role of protein-protein interactions and implications in disease states. Biochimica et Biophysica Acta 2009, 1791:646-658.
151. Rossier M.F. T channels and steroid biosynthesis: in search of a link with mitochondria. Cell Calcium 2006, 40:155-164.
152. Roth B.L., Sheffler D.J., Kroeze W.K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nature Reviews. Drug Discovery 2004, 3:353-359.
153. Rudolph U., Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nature Reviews. Drug Discovery 2011, 10:685-697.
154. Rupprecht R., Papadopoulos V., Rammes G., Baghai T.C., Fan J., Akula N., Groyer G., Adams D., Schumacher M. Translocator protein (18kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nature Reviews. Drug Discovery 2010, 9:971-988.
155. Rupprecht R., Rammes G., Eser D., Baghai T.C., Schule C., Nothdurfter C., Troxler T., Gentsch C., Kalkman H.O., Chaperon F., Uzunov V., McAllister K.H., Bertaina-Anglade V., La Rochelle C.D., Tuerck D., Floesser A., Kiese B., Schumacher M., Landgraf R., Holsboer F., Kucher K. Translocator protein (18kD) as target for anxiolytics without benzodiazepine-like side effects. Science 2009, 325:490-493.
156. A receptor-modulating 3α-hydroxy, 5α-reduced pregnane steroids in the adult rat brain. Journal of Neuroendocrinology 2007, 19:272-284.
157. Sanacora G., Mason G.F., Krystal J.H. Impairment of GABAergic transmission in depression: new insights from neuroimaging studies. Critical Reviews in Neurobiology 2000, 14:23-45.
158. Sandi C. Glucocorticoids act on glutamatergic pathways to affect memory processes. Trends in Neurosciences 2011, 34:165-176.
159. Sanna E., Talani G., Busonero F., Pisu M.G., Purdy R.H., Serra M., Biggio G. Brain steroidogenesis mediates ethanol modulation of GABA-A receptor activity in rat hippocampus. The Journal of Neuroscience 2004, 24:6521-6530.
160. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., Weisstraub N., Lee J., Duman R., Arancio O., Belzung C., Hen R. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
161. A receptors. The Journal of Neuroscience 2011, 31:18198-18210.
162. Sasso O., Russo R., Vitiello S., Raso G.M., D'Agostino G., Iacono A., Rana G.L., Vallee M., Cuzzocrea S., Piazza P.V., Meli R., Calignano A. Implication of allopregnanolone in the antinociceptive effect of N-palmitoylethanolamine in acute or persistent pain. Pain 2012, 153:33-41.
163. Schlichter R., Keller A.F., Do Roo M., Breton J.D., Inquimbert P., Poisbeau P. Fast nongenomic effects of steroids on synaptic transmission and role of endogenous neurosteroids in spinal pain pathways. Journal of Molecular Neuroscience 2006, 28:33-51.
164. Schule C., Eser D., Baghai T.C., Nothdurfter C., Kessler J.S., Rupprecht R. Neuroactive steroids in affective disorders: target for novel antidepressant or anxiolytic drugs?. Neuroscience 2011, 191:55-77.
165. Selye H. Anesthetic effect of steroid hormones. Proceedings of the Society for Experimental Biology and Medicine 1941, 46:116-121.
166. Shen H., Gong Q.H., Aoki C., Yuan M., Ruderman Y., Dattilo M., Williams K., Smith S.S. Reveral of neurosteroid effects at alpha4beta2delta GABAA receptors triggers anxiety at puberty. Nature Neuroscience 2007, 10:469-477.
167. Shen Q., Lal R., Luellen B.A., Earnheart J.C., Andrews A.M., Luscher B. Gamma-aminobutyric acid-type A receptor deficits cause hypothalamic-pituitary-adrenal axis hyperactivity and antidepressant drug sensitivity reminiscent of melancholic forms of depression. Biological Psychiatry 2010, 68:512-520.
168. A receptor desensitization. The Journal of Neuroscience 2000, 20:3571-3579.
169. A receptors. Neuropharmacology 1999, 38:267-271.
170. Shibuya K., Takata N., Hojo Y., Furukawa A., Yasumatsu N., Kimoto T., Enami T., Suzuki K., Tanabe N., Ishii H., Mukai H., Takahashi T., Hattori T., Kawato S. Hippocampal cytochrome P450s synthesize brain neurosteroids which are paracrine neuromodulators of synaptic signal transduction. Biochimica et Biophysica Acta 2003, 1619:301-316.
171. A receptors expressed in Xenopus oocytes. British Journal of Pharmacology 2012, 165:2228-2243.
172. Shu H-J., Eisenman L.N., Jinadasa D., Covey D.F., Zorumski C.F., Mennerick S. Slow actions of neuroactive steroids at GABA-A receptors. The Journal of Neuroscience 2004, 24:6667-6675.
173. Snyder J.S., Soumier A., Brewer M., Pickel J., Cameron H.A. Adult hippocampal neurogenesis buffers stress responses and depressive behaviors. Nature 2011, 476:458-461.
174. A receptor subunits in the rat hippocampus I: immunocytochemical distribution of 13 subunits. Neuroscience 1997, 80:987-1000.
175. A receptors. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:14439-14444.
176. Strohle A., Romeo E., Hermann B., Pasini A., Spalletta G., di Michele F., Holsboer F., Rupprecht R. Concentrations of 3 alpha-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. Biological Psychiatry 1999, 45:274-277.
177. Surget A., Tanti A., Leonardo E.D., Laugeray A., Rainer Q., Touma C., Palme R., Griebel G., Ibarguen-Vargas Y., Hen R., Belzung C. Antidepressants recruit new neurons to improve stress response regulation. Molecular Psychiatry 2011, 16:1177-1188.
178. Sylvester C.M., Corbetta M., Raichle M.E., Rodebaugh T., Schlaggar B.L., Sheline Y.I., Zorumski C.F., Lenze E.J. Functional network dysfunction in anxiety and anxiety disorders. Trends in Neurosciences 2012, 35:527-535.
179. 2+ channels in rat sensory neurons in vitro and potent peripheral analgesics in vivo. Molecular Pharmacology 2004, 66:1223-1235.
180. 2+ current in adult rat sensory neurons by a steroid lacking GABA-modulatory activity. Molecular Pharmacology 1998, 54:918-927.
181. Tokuda K., Izumi Y., Zorumski C.F. Ethanol enhances neurosteroidogenesis in hippocampal pyramidal neurons by paradoxical NMDA receptor activation. The Journal of Neuroscience 2011, 31:9905-9909.
182. Tokuda K., O'Dell K.A., Izumi Y., Zorumski C.F. Midazolam inhibits hippocampal long-term potentiation and learning through dual central and peripheral benzodiazepine receptor activation and neurosteroidogenesis. The Journal of Neuroscience 2010, 30:16788-16795.
183. Turner D.M., Ransom R.W., Yang J.S-J. Olsen RW: steroid anesthetics and naturally occurring analogs modulate the (-aminobutyric acid receptor complex at a site distinct from barbiturates. The Journal of Pharmacology and Experimental Therapeutics 1989, 248:960-966.
184. Ugale R.R., Hirani K., Morelli M., Chopde C.T. Role of neuroactive steroid allopregnanolone in antipsychotic-like action of olanzepine in rodents. Neuropsychopharmacology 2004, 29:1597-15609.
185. Uzunov D.P., Cooper T.B., Costa E., Guidotti A. Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:12599-12604.
186. Uzunova V., Sheline Y., Davis J.M., Rasmusson A., Uzunov D.P., Costa E., Guidotti A. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:3239-3244.
187. Valdez C.M., Smith M.A., Perry G., Phelix C.F., Santamaria F. Cholesterol homeostasis markers are localized to mouse hippocampal pyramidal and granule layers. Hippocampus 2010, 20:902-905.
188. Valenzuela C.F., Partridge L.D., Mameli M., Meyer D.A. Modulation of glutamatergic transmission by sulfated steroids: role in fetal alcohol spectrum disorder. Brain Research Reviews 2008, 57:506-519.
189. Vallee M., Rivera J.D., Koob G.F., Purdy R.H., Fitzgerald R.L. Quantification of neurosteroids in rat plasma and brain following swim stress and allopregnanolone administration using negative chemical ionization gas chromatography/mass spectrometry. Analytical Biochemistry 2000, 287:153-166.
190. VanDoren M.J., Matthews D.B., Janis G.C., Grobin A.C., Devaud L.L., Morrow A.L. Neuroactive steroid 3alpha-hydroxy-5alpha-pregnan-20-one modulates electrophysiological and behavioral actions of ethanol. The Journal of Neuroscience 2000, 20:1982-1989.
191. Wang J.M., Singh C., Liu L., Irwin R.W., Chen S., Chung E.J., Thompson R.E., Brinton R.D. Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:6498-6503.
192. A-receptor antagonists. The Journal of Neuroscience 2002, 22:3366-3375.
193. A receptor modulation and anesthesia. Molecular Pharmacology 1996, 50:1581-1586.
194. Wohlfarth K.M., Bianchi M.T., Macdonald R.L. Enhanced neurosteroid potentiation of ternary GABA (A) receptors containing the delta subunit. The Journal of Neuroscience 2002, 22:1541-1549.
195. Wu F.S., Gibbs T.T., Farb D.H. Pregnenolone sulfate: a positive allosteric modulator at the N-methyl-D-aspartate receptor. Molecular Pharmacology 1991, 40:333-336.
196. Yamakura T., Bertaccini E., Trudell J.R., Harris R.A. Anesthetics and ion channels: molecular models and sites of action. Annual Review of Pharmacology and Toxicology 2001, 41:23-51.
197. Yang J., Isenberg K.E., Zorumski C.F. Volatile anesthetics gate a chloride current in postnatal rat hippocampal neurons. The FASEB Journal 1992, 6:914-918.
198. Yang P-C., Yang C-H., Huang C-C., Hsu K-S. Phosphatidylinositol 3-kinase activation is required for stress protocol-induced modification of hippocampal synaptic plasticity. The Journal of Biological Chemistry 2008, 283:2631-2643.
199. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., Charney D.S., Manji H.K. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 2006, 63:856-864.
200. Zorumski C.F., Izumi Y. NMDA receptors and metaplasticity: mechanisms and possible roles in neuropsychiatric disorders. Neuroscience and Biobehavioral Reviews 2012, 36:989-1000.
201. Zorumski C.F., Mennerick S., Covey D.F. Enantioselective modulation of GABAergic synaptic transmission by steroids and benz[e]indenes in hippocampal microcultures. Synapse 1998, 29:162-171.
202. Zorumski C.F., Mennerick S., Isenberg K.E., Covey D.F. Potential clinical uses of neuroactive steroids. Current Opinion in Investigational Drugs 2000, 1:360-369.
203. Zorumski C.F., Rubin E.H. Psychiatry and Clinical Neuroscience: A Primer 2011, Oxford University Press, New York.